首页 正文

Biosimilars: a cure to the U.S. health care cost conundrum?

{{output}}
As the cost of healthcare continues to rise and patents on biologics near expiration, biosimilars are gaining visibility as a mechanism for cost reduction. Yet, the introduction of biosimilars into the U.S. market will be complex, due to the related complexity... ...